Clinical trials: Advanced Cancer
Neuroblastoma
Therapy for Children With Neuroblastoma
This is a phase II window study of the combination of ZD1839 (gefitinib) and irinotecan in children with high-risk neuroblastoma followed by standard induction chemotherapy, intensification with autologous stem cell…
- Trial name
- NCT00135135
- Testing
- Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acid, Radiation therapy, Surgery, Peripheral Stem cell transplant
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- St. Jude Children's Research Hospital
Advanced Cancers and FGFR Genetic Alterations
Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment Options
The purpose of this program is to provide participants an early access to erdafitinib prior to market authorization (that is, Food and Drug Administration [FDA] approval in the United States).
- Trial name
- NCT03825484
- Testing
- Erdafitinib
- Sponsor
- Janssen Scientific Affairs, LLC
Cholangiocarcinoma
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy
This is a single arm, multicentre, Phase 2 study to assess efficacy and safety of ASLAN001 in patients with advanced or metastatic cholangiocarcinoma who progressed on at least 1 line of systemic therapy.
- Trial name
- NCT02609958
- Testing
- Varlitinib
- Where
- 3 sites in Singapore, South Korea and 1 more
- Volunteers
- 32 people
- Sponsor
- ASLAN Pharmaceuticals
Gastrointestinal Stromal Tumors
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Children and young adults with gastrointestinal stromal tumors (GIST) will be treated with sunitinib. The safety (including pharmacokinetics) and tolerability of sunitinib will be studied in these patients.
- Trial name
- NCT01396148
- Testing
- sunitinib malate dose escalation, sunitinib malate
- Where
- 9 sites in United States, Czechia and 1 more
- Volunteers
- 6 people
- Sponsor
- Pfizer
GIST
Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST
This is a US, multicenter, open-label expanded access program to provide access to avapritinib until such time that avapritinib becomes available through other mechanisms or the Sponsor chooses to discontinue the program.
- Trial name
- NCT03862885
- Testing
- Avapritinib
- Sponsor
- Blueprint Medicines Corporation
Advanced Cancer
Cancer Patients' Medication Knowledge in the Emergency Center
The goal of the study is to learn about patients' knowledge of their medications in an outpatient acute care setting (such as the M. D.
- Trial name
- NCT00385476
- Testing
- PMKT Questionnaire
- Where
- United States
- Volunteers
- 308 people
- Sponsor
- M.D. Anderson Cancer Center
Osteosarcoma, Neuroblastoma
Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor
Cd276 (B7-H3) is an ideal target for car-t treatment because of its high expression on the surface of neuroblastoma, osteosarcoma, gastric cancer and lung cancer cells, but not in normal peripheral cells or tissues.
- Conditions
- Osteosarcoma, Neuroblastoma, Gastric Cancer, Lung Cancer
- Trial name
- NCT04864821
- Testing
- Targeting CD276 CAR T cells
- Volunteers
- 24 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well olaparib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with defects in deoxyribonucleic acid (DNA) damage repair genes that have…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Low Grade Glioma
- Trial name
- NCT03233204
- Testing
- Olaparib
- Where
- 113 sites in United States, Puerto Rico
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Soft Tissue Sarcoma (STS), Osteosarcoma
Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma
The main purpose of this trial is to investigate and evaluate the efficacy of cryoablation combined with camrelizumab treatment to patients with advanced or inoperable soft tissue sarcomas after standard treatment failure.
- Trial name
- NCT07602049
- Testing
- Cryoablation therapy + anti-PD-1 antibody
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Sun Yat-sen University
Melanoma (Skin)
Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301
RATIONALE: Drugs used in chemotherapy, such as dacarbazine, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00070343
- Testing
- oblimersen sodium, dacarbazine
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have stage IV…
- Trial name
- NCT00004149
- Testing
- arsenic trioxide
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Albert Einstein College of Medicine
Advanced Diffuse Large B-Cell Lymphoma, Extra-nodal Involvement, Large Mass
A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete Remission
This study is a prospective, single center, phase II clinical study involving 108 patients with primary and late stage Diffuse Large B-cell Lymphoma complicated by large masses and extranodal involvement.
- Conditions
- Advanced Diffuse Large B-Cell Lymphoma, Extra-nodal Involvement, Large Mass, Radiotherapy
- Trial name
- NCT05874778
- Testing
- 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy, Radiotherapy beyond standard R-CHOP Chemotherapy
- Volunteers
- 108 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Cancer
Valproic Acid and Bevacizumab in Patients With Advanced Cancer
The goal of this clinical research study is to find the highest tolerable dose of bevacizumab in combination with valproic acid that can be given to patients with advanced cancer that has not responded to standard treatment or…
- Trial name
- NCT00530907
- Testing
- Valproic Acid, Bevacizumab
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- M.D. Anderson Cancer Center
Intestinal Anastomotic Leak
Risk Factors for Anatomic Leakage in Advanced Ovarian Cancer Surgery
Cytoreductive surgery is currently the main treatment for advanced epithelial ovarian cancer (AEOC), and the complete disease removal (RT=0) or the achievement of an optimal residual disease (RT < 1 cm) remain the factors with…
- Trial name
- NCT04604964
- Testing
- Evaluation of anastomotic leakage occurrence
- Where
- Italy
- Volunteers
- 515 people
- Sponsor
- Catholic University of the Sacred Heart
Head and Neck Cancer
Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea
After consultation with the Korean Health Authorities, the two Post-Authorization Safety Studies EMR 62202-509 (NCT01082315) and EMR 62241-508 (NCT01075828) were combined within one study protocol EMR 062202-551.
- Trial name
- NCT01075828
- Testing
- Cetuximab
- Where
- South Korea
- Volunteers
- 221 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
S9715, Chemotherapy and Radiation Therapy in Treating Patients With Advanced Cancer of the Nasopharynx
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002999
- Testing
- cisplatin, fluorouracil, radiation therapy
- Sponsor
- SWOG Cancer Research Network
Advanced Cancers
Initiative for Molecular Profiling in Advanced Cancer Therapy (IMPACT) Trial, An Umbrella Protocol
Primary Objective The primary objective of this study is to establish a program for the molecular profiling of patients with advanced cancer, with the goals of (1) providing a comprehensive characterization of the molecular…
- Trial name
- NCT00851032
- Testing
- Molecular Profiling Analyses
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- M.D. Anderson Cancer Center
Stage III Vulvar Cancer, Stage IVB Vulvar Cancer
Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva
This phase II trial is studying how well giving radiation therapy together with cisplatin followed by surgery works in treating patients with locally advanced cancer of the vulva.
- Conditions
- Stage III Vulvar Cancer, Stage IVB Vulvar Cancer, Vulvar Squamous Cell Carcinoma
- Trial name
- NCT00068406
- Testing
- 3-Dimensional Conformal Radiation Therapy, Cisplatin, Conventional Surgery
- Where
- 103 sites in United States
- Volunteers
- 61 people
- Sponsor
- Gynecologic Oncology Group
Cancer
Expanded Access Program to Provide STC-15 to Patients With Selected Advanced Cancer
This Expanded Access Program (EAP) is intended to provide access to STC-15 outside of a clinical study setting for adult and pediatric patients with serious or life-threatening malignancies who, in the opinion of their treating…
- Trial name
- NCT07906093
- Testing
- STC-15
- Sponsor
- STORM Therapeutics LTD
Advanced Cancer
Doxil, Bevacizumab and Temsirolimus Trial
The goal of this clinical research study is to learn the highest safe doses of the combination of Doxil (liposomal doxorubicin), Avastin (bevacizumab), and Torisel (Temsirolimus) that can be given to patients with advanced cancer…
- Trial name
- NCT00761644
- Testing
- Doxil, Bevacizumab, Temsirolimus
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.